A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : DA / darbepoetin alfa

[Related PubMed/MEDLINE]
Total Number of Papers: 107
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   DA  (>> Co-occurring Abbreviation)
Long Form:   darbepoetin alfa
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Long-term maintenance of hemoglobin levels in hemodialysis patients treated with bi-weekly epoetin beta pegol switched from darbepoetin alfa: a single-center, 12-month observational study in Japan. CERA, Hb
2018 Comparative Assessment of the Effect of Hyper-glycosylation on the Pattern and Kinetics of Degradation of Darbepoetin Alfa using a Stability-Indicating Orthogonal Testing Protocol. EPO
2018 Effectiveness of darbepoetin alfa in multiple myeloma patients receiving chemotherapy including novel agents. Hb, MM
2018 [Treatment for low-risk myelodysplastic syndromes]. ESA, MDS
2017 A Comparative Study of the Hemoglobin-Maintaining Effects Between Epoetin-beta Pegol and Darbepoetin-alpha in Patients with Chronic Kidney Disease During 3Months Before Dialysis Initiation. CERA, CKD
2017 Anemia Treatment by Erythropoiesis-stimulating Agents during the 6 Months before the Initiation of Hemodialysis: Comparison of Darbepoetin Alfa and Continuous Erythropoietin Receptor Activator. CERA, CKD, ESAs
2017 Costs Associated With Intravenous Darbepoetin Versus Epoetin Therapy in Hemodialysis Patients: A Randomized Controlled Trial. CI, EPO, ESAs, Hb, IQR
2016 Associations among Erythroferrone and Biomarkers of Erythropoiesis and Iron Metabolism, and Treatment with Long-Term Erythropoiesis-Stimulating Agents in Patients on Hemodialysis. CERA, ERFE, ESA, HD
2016 Effectiveness of Darbepoetin Alfa for Chemotherapy-induced Anemia When Initiated at Hemoglobin ≤10 g/dL. CIA, Hb, HR
10  2016 Efficacy and safety of darbepoetin alfa initiated at hemoglobin ≤10g/dL in patients with stage IV cancer and chemotherapy-induced anemia. CIA, Hb, RBC
11  2016 Efficacy and safety of darbepoetin alpha in patients with myelodysplastic syndromes: a systematic review and meta-analysis. CI, EPO, ESA, IPSS, MDS, QOL
12  2016 Hemoglobin levels and quality of life in patients with symptomatic chemotherapy-induced anemia: the eAQUA study. FACT-F, Hb, PAS, QOL
13  2016 Modulation of circulating endothelial progenitor cells by erythropoiesis-stimulating agents in patients with chronic kidney disease stage G5 and 5D
. CKD G5 and 5D, EPCs, EPO, ESAs, MMP-2, rhEPO
14  2016 Outcomes in patients with chronic kidney disease not on dialysis receiving extended dosing regimens of darbepoetin alfa: long-term results of the EXTEND observational cohort study. CI, CKD-NOD, ESA, Hb
15  2016 Safety and usage of darbepoetin alfa in children with chronic kidney disease: prospective registry study. AEs, CKD, Hb
16  2016 [Switch of methoxy-polyethylene-glycol-epoetin beta to darbepoetin alfa in 263 dialysis patients]. ---
17  2015 A randomized comparison of once weekly epoetin alfa to extended schedule epoetin or darbepoetin in chemotherapy-associated anemia. AEs, CAA, EA, ESAs, Hb, PROs, RBC
18  2015 A randomized controlled trial comparing darbepoetin alfa doses in red blood cell transfusion-dependent patients with low- or intermediate-1 risk myelodysplastic syndromes. ---
19  2015 Comparing the efficacy of continuous erythropoietin receptor activator and darbepoetin Alfa treatments in Japanese patients with chronic kidney disease during the predialysis period: A propensity-matched analysis. CERA, CKD, ERI, ESA, Hb
20  2015 Effects of Long-Term Erythropoiesis-Stimulating Agents on Iron Metabolism in Patients on Hemodialysis. CERA, HD
21  2015 Impact of Switching From Darbepoetin Alfa to Epoetin Beta Pegol on Iron Utilization and Blood Pressure in Peritoneal Dialysis Patients. Hgb, PD, TSAT
22  2015 Increased risk of stroke with darbepoetin alfa in anaemic heart failure patients with diabetes and chronic kidney disease. CI, eGFR, HR, RED-HF
23  2015 Randomized Controlled Trial of Darbepoetin alpha Versus Continuous Erythropoietin Receptor Activator Injected Subcutaneously Once Every Four Weeks in Patients with Chronic Kidney Disease at the Pre-Dialysis Stage. CERA, CKD, Hb
24  2015 Treatment of renal anaemia with erythropoiesis-stimulating agents in predialysis chronic kidney disease patients: Haemoglobin profile during the 6 months before initiation of dialysis. CERA, CKD, ESAs, Hb, rHuEPO
25  2015 Treatment With Darbepoetin During the First Year After Renal Transplantation: The Starting Point. DGF
26  2015 [Comparison of benefits to non-dialysis CKD patients between darbepoetin alpha and epoetin beta pegol]. CERA, CKD, ESAs, Hb, Hct, MCH, MCHC, MCV, RBC
27  2014 A prospective cohort study on the impact of darbepoetin alfa on quality of life in daily practice following anemia treatment guideline revisions. Hb, QOL
28  2014 Darbepoetin alfa administered once every three weeks for the treatment of anemia in elderly patients with non-myeloid tumors receiving chemotherapy. Hb
29  2014 Darbepoetin alfa once every 2 weeks effectively maintained hemoglobin in dialysis patients in an observational study: Austrian cohort of ALTERNATE. AFU
30  2014 Darbepoetin alfa once monthly corrects anaemia in patients with chronic kidney disease not on dialysis. CI, CKD-ND, Hb
31  2014 Effect of occasional epoetin use in combination with a stable darbepoetin dosage on anemia management in hemodialysis patients. DA/EPO, EPO, Hb, HD, vs
32  2014 Efficacy and safety of darbepoetin alfa for anemia in children with chronic kidney disease: a multicenter prospective study in Japan. CKD, HD, PD, rHuEPO, s.c
33  2014 Final results from the prospective phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer. BC, EFS, Hb, OS, QOL
34  2014 Pharmacokinetics of darbepoetin alfa after single, intravenous or subcutaneous administration in Japanese pediatric patients with chronic kidney disease. CKD, CL, Tmax
35  2014 Preservation of anemia control and weekly ESA dosage after conversion from PEG-Epoetin beta to darbepoetin alfa in adult hemodialysis patients: the TRANSFORM study. CI, CKD, Hb, PEG-EPO
36  2013 A Safe and Easy Introduction of Darbepoetin-Alpha in Patients Receiving Maintenance Hemodialysis and Epoetin Monotherapy: A "Half-and-Half" Combination Therapy. EPO, Hb, HD
37  2013 Chemotherapy-induced anemia: the story of darbepoetin alfa. CIA, ESA
38  2013 Comparison of recombinant human erythropoietin and darbepoetin alpha in children. CKD, Hb, rHuEPO
39  2013 Darbepoetin alfa administration in patients with non-Hodgkin lymphoma and chemotherapy-induced anemia receiving (R) CHOP. Hb
40  2013 Darbepoetin alfa for the treatment of anemia in children undergoing peritoneal dialysis: a multicenter prospective study in Japan. Hb, PD, rHuEPO
41  2013 Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation: a prospective multicenter randomized trial. Hb, HCT, i.v
42  2013 Different administration schedules of darbepoetin alfa affect oxidized and reduced glutathione levels to a similar extent in 5/6 nephrectomized rats. ESAs, SHAM
43  2013 Dose conversion ratio in hemodialysis patients switched from darbepoetin alfa to PEG-epoetin beta: AFFIRM study. AFFIRM, CKD, DCR, EP, ESA, Hb, PEG-EPO
44  2013 Hemoglobin level at initiation of darbepoetin alfa: impact on need for transfusion and associated costs in chemotherapy-induced anemia treatment in Europe. Hb
45  2013 Hemoglobin maintenance and dosing strategies using intravenous continuous erythropoietin receptor activator in Japanese hemodialysis patients. CERA
46  2013 Intracoronary administration of darbepoetin-alpha at onset of reperfusion in acute myocardial infarction: results of the randomized Intra-Co-EpoMI trial. AAR, CMR, IS, MI, PCI
47  2013 Re-evaluation of laboratory predictors of response to current anemia treatment regimens of erythropoiesis stimulating agents in cancer patients. EPO, ESA, Hb, sTfR
48  2013 Stable hemoglobin in hemodialysis patients: forest for the trees--a 12-week pilot observational study. Hb
49  2013 Staff time and motion assessment for administration of erythropoiesis-stimulating agents: a two-phase pilot study in clinical oncology practices. ANCOVA, ESAs
50  2013 SureClick (Darbepoetin alfa) can improve perceived satisfaction and competence for anemia treatment and increase self-administration in non-dialyzed patients with chronic kidney disease. ATSQ-S, CKD, PCAS, PFS
51  2013 Synchronization of administrations of chemotherapy and erythropoiesis-stimulating agents and frequency of associated healthcare visits. EA, ESAs
52  2012 A final analysis from the CHOICE study examining darbepoetin alfa use for chemotherapy-induced anaemia in current European clinical practice. FAS, RBC
53  2012 An observational cohort study of extended dosing (once every 2 weeks or once monthly) regimens with darbepoetin alfa in patients with chronic kidney disease not on dialysis: the EXTEND study. CKD, ESA
54  2012 Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses. AEs, CI, ESAs, HR, OR
55  2012 Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy. CIA, ESAs
56  2012 Renal effects of long-term darbepoetin alpha treatment in hypertensive TGR(mRen2)27 rats. ACEI, EPO, KIM-1, SD, VEH
57  2012 Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9 g/dL versus 9 to <10 g/dL versus ≥ 10 g/dL: an exploratory analysis of a phase 3 trial. CIA, ESA, Hb
58  2012 Use of darbepoetin alfa in European clinical practice for the management of chemotherapy-induced anaemia in four tumour types: final data from the CHOICE study. CIA, Hb
59  2012 Utilization and cost in clinical practice of darbepoetin alfa and epoetin alfa for anemia concomitant with chemotherapy. EA, ESAs
60  2011 An observational study of the effectiveness of darbepoetin alpha administered in dialysis patients once every 2 weeks for 12 months. ESAs, Hb
61  2011 Both darbepoetin alfa and carbamylated erythropoietin prevent kidney graft dysfunction due to ischemia/reperfusion in rats. CEPO, EpoR, I/R, p-Akt, PTC
62  2011 Current practice of darbepoetin alfa in the management of haemoglobin levels in cancer patients undergoing chemotherapy - data from the CHOICE study. EORTC, EOTP, Hb, IA, KM, RBC, SmPC
63  2011 Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response. EPO, FACT-F, MaR, MDS, MiR
64  2011 De novo once-monthly darbepoetin alpha treatment for the anemia of chronic kidney disease using a computerized algorithmic approach. CKD, ESAs, Hb
65  2011 Effectiveness of darbepoetin alfa in a cohort of oncology patients with chemotherapy-induced anaemia. Relationship between variation in three fatigue-specific quality of life questionnaire scores and change in haemoglobin level. CIA, CRF, CT, EOCT, FSI, Hb
66  2011 Effects of Darbepoetin Alfa with exercise in cancer patients undergoing chemotherapy: an explorative study. EPO, QOL
67  2011 PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel darbepoetin alfa in primary breast cancer--results at the time of surgery. pCR
68  2011 Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa  filgrastim or erythrocyte transfusions. G-CSF, Hb, MDS, QOL
69  2011 RETRA: evaluating the transfusion rate with darbepoetin alfa 500 g every 3 weeks in anaemic cancer patients receiving chemotherapy. ECOG, EORTC, RBCT
70  2011 Testing a single monthly dose of darbepoetin alpha to maintain hemoglobin levels in continuous ambulatory peritoneal dialysis patients. CAPD, rHuEPO
71  2010 A prospective protocol-based trial of darbepoetin alfa therapy to correct the early anemia following renal transplantation. EPO, PTA
72  2010 A prospective, observational study describing the haematological response in patients undergoing chemotherapy treated by tri-weekly darbepoetin alfa for anaemia. Hb
73  2010 Anemia management with darbepoetin-alfa in outpatient hemodialysis patients switched from epoetin-alfa: a community hospital experience. EA
74  2010 Treatment of anemia with darbepoetin alfa in heart failure. CI, Hb, HF, HRs
75  2010 [Direct medical cost of erythropoiesis-stimulating agents in anaemia treatment of chronic renal failure patient: a literature review]. CRI, EA, ESA, SC
76  2010 [Evolution of the darbepoetin alpha resistance index in patients on dialysis who change from weekly to fortnightly treatments in clinical practice]. ERI, HD, PD
77  2009 A Phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes. G-CSF, MDS, RARS
78  2009 Darbepoetin alpha, a long-acting erythropoeitin derivate, does not alter LPS evoked myocardial depression and gene expression of Bax, Bcl-Xs, Bcl-XL, Bcl-2, and TNF-alpha. LV
79  2009 Drug safety profile of darbepoetin alfa for anemia of chronic kidney disease. ---
80  2009 Lipopolysaccharide evokes resistance to erythropoiesis induced by the long-acting erythropoietin analogue darbepoetin alfa in rats. LPS
81  2009 Observational Aranesp Survey to Investigate the Q3W Schedule (OASIS): a prospective observational study of treatment of chemotherapy-induced anaemia with every 3 weeks darbepoetin alfa. CIA, ESAs, Hb
82  2009 Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. CIA, ESAs
83  2009 Short- and long-term cardioprotective effect of darbepoetin-alpha: role of Bcl-2 family proteins. LV
84  2009 The importance of clinical variables in comparative analyses using propensity-score matching: the case of ESA costs for the treatment of chemotherapy-induced anaemia. ASP, CIA, EA, ESAs, Hb, SE
85  2009 The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failure. AE, Hb, HF
86  2008 A prospective observational study of the effectiveness, safety, and effect on fatigue of darbepoetin alfa for the treatment of chemotherapy-induced anaemia. Hb
87  2008 Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. ---
88  2008 Darbepoetin-alfa in renal-transplant patients: an observational monocentric study. rHuEPO
89  2008 Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. CKD, ESAs, Hb
90  2008 Simultaneous administration of insulin-like growth factor-1 and darbepoetin alfa protects the rat myocardium against myocardial infarction and enhances angiogenesis. EPO, I/R, IGF-1, MI
91  2008 Use of darbepoetin alfa and epoetin alfa in clinical practice in patients with cancer-related anemia. CRA, EA, EOCs, ESAs
92  2008 Utilization of darbepoetin alfa in relation to cancer patients' hemoglobin levels. AOC, CIA, EMRs, ESAs, Hb, MDS
93  2007 Darbepoetin alfa, a long-acting erythropoietin analog, offers novel and delayed cardioprotection for the ischemic heart. EPO, I/R
94  2007 Darbepoetin, effective treatment of anaemia in paediatric patients with chronic renal failure. CRF, Hb, rHuEPO
95  2007 Dose requirements among hemodialysis patients treated with darbepoetin-alpha or epoetin-beta. EB, ESA, s.c
96  2007 Lymphatic absorption of subcutaneously administered proteins: influence of different injection sites on the absorption of darbepoetin alfa using a sheep model. ---
97  2006 Darbepoetin alpha for the treatment of anemia in patients with myelodysplastic syndromes. ESP, MDS, RA, RAEB, rHuEPO
98  2006 Effect of darbepoetin alfa on physical function in patients undergoing surgery for colorectal cancer. A randomized, double-blind, placebo-controlled study. Hb, QOL
99  2006 Efficacy of darbepoetin in doxorubicin-induced cardiorenal injury in rats. DXR
100  2006 Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial. EA